← The record

TezepelumabTezspire

Recommended RespiratoryAuthority RequiredLater-line line 💬 consumer voice

Add-on maintenance treatment in patients aged 12 years and older with severe uncontrolled asthma (both eosinophilic/allergic and non-eosinophilic/non-allergic phenotypes) who are inadequately controlled despite optimal therapy including medium or high-dose inhaled corticosteroids plus another non-steroidal medicinal product for maintenance treatment.

1
Submissions
1 resub
2025–25
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis

Decisions on record

2 decisions
  • Meeting Nov 2025 Recommended Severe uncontrolled asthma in patients aged 12+ years (non-eosinophilic/non-allergic and eosinophilic/allergic phenotypes)
  • Meeting Jul 2022 Withdrawn Asthma, severe uncontrolled allergic and/or eosinophilic no PSD

Access path

1 submission · public record
  1. TGA registered · Tezspire

    TGA label narrower than the PBS population

  2. Nov 2025
    Recommended · restricted

    vs Standard of care for non-eosinophilic/non-allergic SUA…

  3. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended the Section 100 (Highly Specialised Drugs Program [HSD]) listing of tezepelumab for the treatment of patients aged 12 years and older with severe uncontrolled asthma (SUA) that is non-eosinophilic and non-allergic. The PBAC was satisfied that tezepelumab provides, for some patients, a significant improvement in efficacy over standard of care (SoC).PSD · Nov 2025
7.2 The PBAC recommended the Section 100 (HSD) listing of tezepelumab for the treatment of patients aged 12 years and older with SUA that is eosinophilic or allergic.PSD · Nov 2025
Economic analysis
6.45 The submission presented a stepped economic evaluation of tezepelumab compared to SoC in patients with non-eosinophilic and non-allergic SUA who require high-dose ICS.PSD · Nov 2025
6.46 The type of economic evaluation presented was a cost-utility analysis and cost- effectiveness approach. The cost-utility analysis was consistent with the clinical claim of superior effectiveness and non-inferior safety of tezepelumab compared to SoC for the population.PSD · Nov 2025
Clinical claim
6.36 For the non-eosinophilic and non-allergic SUA population, the submission described tezepelumab as superior in terms of effectiveness compared to placebo. The ESC noted the following uncertainties regarding the data presented in the submission:PSD · Nov 2025
4 Results from the SUA subgroup of patients with non-EOSic (<300cells/µl) + non-allergic (perennial specific IgE status negative) + high ICSPSD · Nov 2025
Consumer comments
6.2 The PBAC noted and welcomed input from health care professionals (2), a medical organisation (1) and a consumer group/organisation (1) via the Office of Health Technology Assessment Consultation Hub. Health care professional input emphasised that there is a clinical need for patients with T2-low biomarkers (non-eosinophilic and non-allergic) as they are ineligible, and not suitable, for biologics currently subsidised through the PBS.PSD · Nov 2025
Financial management – risk sharing
6.96 The submission did not propose a risk-sharing arrangement, stating that it was consistent with the arrangements for the current asthma biologics. For more detail on PBAC’s view, see section 7 PBAC outcome.PSD · Nov 2025

Cost-effectiveness

ICER values redacted (commercially sensitive) for non-eosinophilic/non-allergic population; cost-minimisation approach used for eosinophilic/allergic population versus dupilumab.

Decision context

PopulationPatients aged 12 years and older with severe uncontrolled asthma (non-eosinophilic/non-allergic or eosinophilic/allergic phenotypes) inadequately controlled despite optimised high-dose inhaled corticosteroid plus long-acting beta-2 agonist therapy.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2025 Recommended · restricted Standard of care for non-eosinophilic/non-allergic SUA; dupilumab for eosinophilic/allergic SUA RCT · AAER

Consumer voice

Nov 2025

Healthcare professionals and consumer organisations expressed support for PBS listing of tezepelumab, highlighting unmet clinical need for T2-low asthma patients ineligible for current biologics, favourable side effect profile compared to long-term oral corticosteroids, and the importance of equitable access to treatment and quality of life improvements.

Health care professional input emphasised that there is a clinical need for patients with T2-low biomarkers (non-eosinophilic and non-allergic) as they are ineligible, and not suitable, for biologics currently subsidised through the PBS. Consumer comments · PSD
unmet needside effectsquality of lifeaccess barrierstreatment burden

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to severe uncontrolled asthma with specified phenotypes and includes later-line positioning; TGA label is broader.